XOMA - XOMA Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.31
+0.29 (+1.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.02
Open18.00
Bid17.86 x 800
Ask20.75 x 1200
Day's Range17.85 - 18.68
52 Week Range11.02 - 22.00
Volume44,601
Avg. Volume46,255
Market Cap159.803M
Beta (3Y Monthly)0.39
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets

    XOMA Corporation (XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.  One of the assets, NIR178, is being developed by Novartis as a novel checkpoint inhibitor for the treatment of solid tumors.  Five of the assets are being developed by Palobiofarma.

  • GlobeNewswire

    XOMA to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will provide a corporate update at the 2019 Cantor Fitzgerald Global Healthcare Conference, taking place October 2-4, 2019, in New York, New York.  The presentation will take place on Wednesday, October 2, 2019 at 7:45AM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com.  An archived version of the webcast will be available for 90 days after the event. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  For more information, visit www.xoma.com.

  • GlobeNewswire

    XOMA to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the H.C. Wainwright 21st Annual Global Investment Conference, in New York, New York.  The presentation will take place on Tuesday, September 10, 2019, at 10:00AM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com or by clicking http://wsw.com/webcast/hcw5/xoma/.  An archived version of the webcast will be available for 90 days after the event. EXPLANATORY NOTE: All references to “portfolio” in this press release are to milestone and/or royalty rights associated with drug products in development.  All references to “assets” in this presentation are to milestone and/or royalty rights associated with individual drug products in development.

  • GlobeNewswire

    XOMA’s Royalty Portfolio Expands Significantly

    XOMA Corporation (XOMA), today announced its portfolio of potential future royalty and milestone payments has significantly increased with the addition of Janssen Biotech, Inc. drug candidates for which XOMA could receive future milestone and royalty payments. In addition, Janssen has elected to accelerate its base annual license fee obligation and will make a one-time $2.5 million payment to XOMA. For each program, XOMA is entitled to receive milestone payments upon the achievement of certain clinical development and regulatory approval events.

  • GlobeNewswire

    XOMA Reports Second Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results

    Novartis’s iscalimab highlighted at key scientific conferences First patient dosed with gevokizumab in collaborator clinical study Sesen Bio announced intention to initiate.

  • GlobeNewswire

    XOMA to Present at the 2019 Wedbush PacGrow Healthcare Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the 2019 Wedbush PacGrow Healthcare Conference in New York, New York.  The presentation will take place on Wednesday, August 14, 2019, at 3:40PM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com or by clicking http://wsw.com/webcast/wedbush35/xoma/.  An archived version of the webcast will be available for 90 days after the event. EXPLANATORY NOTE: All references to “portfolio” in this press release are to milestone and/or royalty rights associated with drug products in development.  All references to “assets” in this presentation are to milestone and/or royalty rights associated with individual drug products in development.

  • GlobeNewswire

    First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma

    XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.  For more information, visit www.xoma.com.

  • GlobeNewswire

    XOMA Reports First Quarter 2019 Financial Results and Operating Highlights

    Acquired rights to potential milestone and royalty payments associated with five hematology assetsReceived $5.5 million milestone paymentAdded Barbara Kosacz to XOMA’s Board of.

  • GlobeNewswire

    XOMA Acquires Royalty Rights to Five Hematology Candidates

    EMERYVILLE, Calif., April 08, 2019 -- XOMA Corporation (NASDAQ: XOMA) announced today it has agreed to acquire the rights to potential royalty payments and a portion of the.

  • GlobeNewswire

    XOMA to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the 2019 H.C. Wainwright Global Life Sciences in London, United Kingdom.  The presentation will take place on Tuesday, April 9, 2019, at 11:50AM BST (6:50 AM ET), and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com.  An archived version of the webcast will be available for 90 days after the event. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future.  For more information, visit www.xoma.com.

  • GlobeNewswire

    XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights

    Added seven new partner-funded programs in 2018 with potential for milestone and royalty paymentsCurrent cash balance sufficient to fund operations for multiple years.

  • GlobeNewswire

    XOMA to Present at the Cowen and Company 39th Annual Health Care Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts.  The presentation will take place on Tuesday, March 12, 2019, at 12:00PM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com.  An archived version of the webcast will be available for 90 days after the event. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future.  For more information, visit www.xoma.com.

  • GlobeNewswire

    XOMA Receives $5.5 Million Payment from Rezolute

    XOMA Corporation (XOMA) announced today it has received a $5.5 million payment from Rezolute, Inc., related to the Companies’ 2017 license agreement, as most recently amended on January 7, 2019. “Our business model is fundamentally designed to generate significant long-term royalty-based revenue as the underlying assets are commercialized.  Moreover, many of our license agreements include the potential for XOMA to receive significant milestone payments as the licensed assets progress.  The receipt of this milestone payment is a good example of XOMA further strengthening its balance sheet with additional non-dilutive capital.  This capital can be deployed to further expand our portfolio of assets from which we have the potential to earn future milestone payments and royalties,” commented Jim Neal, Chief Executive Officer at XOMA.

  • GlobeNewswire

    XOMA Announces Barbara Kosacz Joins its Board of Directors

    EMERYVILLE, Calif., Jan. 03, 2019 -- XOMA Corporation (NASDAQ: XOMA) announced today Barbara Kosacz, a Partner at Cooley LLP, has joined the Company’s Board of Directors.  Ms..

  • GlobeNewswire

    XOMA Announces Closing of Rights Offering

    The Rights Offering was made pursuant to the Company’s effective shelf registration statement on file with the Securities and Exchange Commission (“SEC”) and a prospectus supplement and accompanying prospectus filed with the SEC on November 19, 2018.  XOMA has engaged D.F. King & Co., Inc., to act as information agent with respect to the Rights Offering. For questions regarding the Rights Offering, or to obtain copies of the Rights Offering prospectus and any related materials, please contact D.F. King & Co. at xoma@dfking.com or by telephone at +1 866-721-1324.

  • GlobeNewswire

    XOMA Announces Commencement of Rights Offering

    EMERYVILLE, Calif., Nov. 19, 2018 -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to.

  • GlobeNewswire

    XOMA Announces Proposed Rights Offering

    Rights Offering will be available to all shareholders of record on November 16, 2018$20 million to be raisedFully backstopped by BVF Partners L.P. EMERYVILLE, Calif., Nov. 07,.

  • GlobeNewswire

    XOMA Reports Third Quarter 2018 Financial Results

    EMERYVILLE, Calif., Nov. 07, 2018 -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator, today announced its third quarter 2018 financial results.  “The third.

  • GlobeNewswire

    Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors

    Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today announced the appointments of James R. Neal and James Sapirstein to its board of directors.  With more than three decades of life science industry experience each, Mr. Neal and Mr. Sapirstein provide Leading BioSciences with broad expertise in such areas as drug development and commercialization, strategic business operations, financial management and business development transactions. Mr. Neal, who currently serves as chief executive officer and board member for XOMA Corporation (XOMA), has nearly 35 years of life science industry leadership experience.  His expertise spans such areas as development and commercialization of novel technologies and products, as well as formation and oversight of successful global business and technology collaborations.  In his current role at XOMA, Mr. Neal spearheaded and secured the requisite capital to support a strategic transition of the company’s operations to focus on a royalty monetization model.  Prior to XOMA, Mr. Neal served as acting chief executive officer of Entelos, Inc, a leader in bio-simulation technologies, at which he was responsible for partnerships with global pharmaceutical companies such as Eli Lilly and GlaxoSmithKline.  He was chief executive officer at Iconix Biosciences at the time it was acquired by Entelos in 2007.  While at Iconix, Mr. Neal was credited with establishing multi-year collaborations with Bristol-Myers Squibb, Abbott Labs, Eli Lilly and the U.S. Food and Drug Administration.  He also previously served as executive vice president of Incyte Genomics, where he led the global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis and Schering-Plough, as well as sales, marketing and business development activities for the company.